Coagulation Device Energy Control for Tissue Impedance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing tissue coagulation devices rely on impedance measurements between two electrodes, which do not accurately account for local specific tissue impedance variations, leading to potential inaccuracies in treatment progress, especially in inhomogeneous tissues.
Innovation Solution
A device with a controllable electric source connected to electrodes, featuring a monitoring unit that determines and integrates energy output during the initial phase of tissue coagulation to control the subsequent phases, ensuring even coagulation by adapting energy application based on the tissue area influenced, using active or apparent power to manage the transition from impedance decrease to increase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If tissue impedance is measured between two electrodes to control coagulation, then the coagulation process can be monitored, but the local specific tissue impedance variations are not accurately determined, leading to potential inaccuracies in treatment progress
Solution Approach 1:
The patent divides the tissue treatment area into multiple segments by using multiple electrodes (first electrode, second electrode, third electrode) instead of a single measurement point. Each electrode pair provides impedance measurements for different local regions, enabling segmentation of the tissue into zones with potentially different impedance characteristics. This resolves the contradiction by maintaining overall monitoring capability while capturing local variations that were previously lost.
Solution Approach 2:
The patent transitions from single-point impedance measurement to multi-point spatial measurement by introducing additional electrodes at different positions. This adds a spatial dimension to the impedance measurement, transforming it from a scalar value to a distributed field measurement. The multiple measurement points provide information about impedance distribution across the tissue, resolving the information loss about local variations.
2Productivity
If energy is applied to tissue during phase I when impedance decreases, then tissue coagulation is initiated, but the energy application may be insufficient or excessive for the actual tissue area influenced
Solution Approach 1:
The patent implements feedback control by continuously monitoring tissue impedance during phase I and using this information to regulate energy application. The impedance changes provide real-time feedback about the coagulation state and tissue properties, allowing the system to adjust energy delivery to match the actual tissue conditions. This resolves the contradiction by ensuring energy application is both sufficient for effective coagulation and precisely matched to the tissue area being treated.
Solution Approach 2:
The patent dynamically changes energy application parameters (power, duration, intensity) based on measured impedance values and the determined tissue area. By adjusting these parameters in response to real-time measurements, the system optimizes coagulation effectiveness while preventing under- or over-treatment. This resolves the contradiction between coagulation speed and uniformity by adapting energy delivery to actual tissue conditions.
3Extent of automation
If the coagulation process is controlled based on overall tissue impedance, then the process can be automated, but the control may be incorrect for inhomogeneous tissues with varying local impedance
Solution Approach 1:
The patent segments the tissue into multiple measurement zones using multiple electrode pairs, allowing automated control to account for local impedance variations. Each segment's impedance characteristics are measured and used to inform the overall control decision, enabling automated adjustment for inhomogeneous tissue properties. This resolves the contradiction by maintaining automation while improving reliability through localized measurements.
Solution Approach 2:
The patent implements dynamic control that adapts to changing tissue conditions during the coagulation process. The system continuously updates its model of tissue properties based on real-time impedance measurements from multiple electrodes, allowing the automated control algorithm to respond to inhomogeneities and variations that arise during treatment. This resolves the contradiction by making the automated control system flexible and adaptive rather than rigid.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach ensures precise control over tissue coagulation phases, ensuring even tissue coagulation and fusion by accurately determining energy input and adapting energy application to the tissue area, reducing the risk of incomplete fusion due to electrode misalignment or fluid seepage.
Implementation Method 1
an electric source (18) which is connected or can be connected to electrodes (12, 13) for influencing biological tissue (11) with current
Implementation Method 2
the tissue runs through a first phase I, during which the tissue impedance decreases considerably
Implementation Method 3
The monitoring unit (23) thus determines at least an electric variable, which characterizes the energy
Implementation Method 4
The control unit (22) controls the source (18) in the second operating phase by means of the energy (active energy or apparent energy), which was established during the first operating phase
Data Source
AI summary
A device (10) for tissue coagulation, in particular for fusion, encompasses an electric source (18), which is connected or which can be connected to electrodes (12, 13) for influencing biological tissue (11) with current. A control unit (22) controls the source (18) during phases I and II of the tissue fusion. These phases I and II correspond to operating phases I, II and III of the device (10). During operating phase I, a monitoring unit (23) determines the energy E1, which is applied into the tissue (11). In the subsequent operating phases II and III, the control unit (22) controls the source (18) by means of the determined energy E1. Such a device turns out to be particularly reliable and to be robust in use.